Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Results 1 - 20 of 51 : 1 2 3 Next »

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/10/2014 2:49:43 PM : Outperform Start Price: $23.22 SRPT Score: +3.64

beaten down more than it should be

Recs

0
Member Avatar Redbeagle (< 20) Submitted: 3/17/2014 12:07:55 PM : Outperform Start Price: $27.23 SRPT Score: -10.46

Good drug pipeline

Recs

0
Member Avatar mulledover (81.48) Submitted: 3/15/2014 11:59:06 AM : Outperform Start Price: $27.38 SRPT Score: -11.31

Phase ii results in duchenne prove their capabilities although this will likely take 2-3 years for further trials. However it's their RNA platform that makes this an interesting company for antiviral drugs for infectious diseases

Recs

0
Member Avatar manirg (41.06) Submitted: 1/27/2014 12:41:25 PM : Outperform Start Price: $23.28 SRPT Score: -0.09

Its drug is only the treatment for DMD. FDA is likely to approve it sooner or later. Hugh long term potential.

Recs

0
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $24.65 SRPT Score: -5.11

The only game in town when it comes to Duchenne Muscular Dystophy.

Recs

0
Member Avatar ferrariedgardo (30.19) Submitted: 1/16/2014 6:57:41 PM : Outperform Start Price: $27.37 SRPT Score: -12.10

DMD trial going well

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $32.49 SRPT Score: +36.81

Short. Biopharma. Sells more stock than has revenues. Revs declining too.

Recs

3
Member Avatar EllenBrandtPhD (< 20) Submitted: 8/17/2013 2:58:48 PM : Outperform Start Price: $32.59 SRPT Score: -37.80

This is a terrifying stock, because its moves tend to be so dramatic.

If you calculate its next Big Turn correctly, either on the downside or the upside, you can make out like a bandit.

The technical picture could hardly have been worse prior to Friday's big up day, but there were many hints something was brewing. It came in the form of a key analyst upgrade and a new Propaganda push beginning Friday.

I think it may continue and that the next Big Turn - Propaganda leading Technicals - may be here.

Recs

3
Member Avatar TMFBiologyFool (98.65) Submitted: 7/24/2013 4:31:02 PM : Outperform Start Price: $37.00 SRPT Score: -44.86

Over punished on delay of FDA decision about surrogate endpoint. Should trend back up as we get closer to FDA decision.

Recs

1
Member Avatar Momentum21 (96.33) Submitted: 7/24/2013 11:34:22 AM : Outperform Start Price: $39.73 SRPT Score: -48.90

sold a little off at 46, back in at 39.99. Too many seem to like this ticker for my taste but that's OK...

https://twitter.com/Momentum21Fund

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:39:26 PM : Outperform Start Price: $38.75 SRPT Score: -48.62

right drug at the right time

Recs

0
Member Avatar IBDContrarian (< 20) Submitted: 4/6/2013 1:51:34 PM : Underperform Start Price: $37.06 SRPT Score: +54.20

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 99 EB NO EARN

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:34:43 PM : Outperform Start Price: $30.37 SRPT Score: -42.48

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Recs

0
Member Avatar ravikaza2 (< 20) Submitted: 3/3/2013 7:57:45 PM : Outperform Start Price: $30.37 SRPT Score: -42.48

Only new treatment for DMD

Recs

0
Member Avatar NHWeston102 (81.52) Submitted: 2/1/2013 10:27:17 AM : Outperform Start Price: $27.48 SRPT Score: -34.86

Fast track approval, followed by pruce spike, followed by a big pharma buy out!! A good company that has done a good thing and deserves all the best - as do its buyers.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:47:23 AM : Outperform Start Price: $25.98 SRPT Score: -35.52

Will receive the first ever FDA breakthrough designation for their lead drug.

Recs

0
Member Avatar SnarkyContrarian (65.64) Submitted: 12/7/2012 12:09:34 PM : Underperform Start Price: $26.45 SRPT Score: +39.05

Shenanigans.

Recs

0
Member Avatar topinvestorkyle (< 20) Submitted: 10/6/2012 1:25:17 PM : Underperform Start Price: $35.50 SRPT Score: +59.28

A garbage company rise

Recs

1
Member Avatar Newt805 (69.17) Submitted: 10/4/2012 4:27:06 PM : Outperform Start Price: $4.14 SRPT Score: +448.44

Is this another NVR?

Recs

0
Member Avatar campwt00global (34.52) Submitted: 9/18/2012 1:52:36 PM : Underperform Start Price: $15.76 SRPT Score: -27.41

had its run...lookout below!

Results 1 - 20 of 51 : 1 2 3 Next »

Featured Broker Partners


Advertisement